Nuclear Magnetic Resonance (NMR)-Based Metabolomic Characterisation of Vitreoretinal Diseases Using Vitreous Fluid

What this Trial Is About

Researchers are studying metabolomics profiles in vitreoretinal diseases such as idiopathic macular hole (IMH), diabetic retinopathy (DR), retinal detachment (RD), idiopathic macular epiretinal membrane (IMM), and retinal vein occlusion (RVO). The goal is to identify abnormal biomarkers using nuclear magnetic resonance (NMR) analysis of vitreous fluid to better understand disease mechanisms and aid in prevention, early diagnosis, and treatment. Participants are grouped by their specific diagnosis, with the IMH group serving as a control group representing the closest to normal vitreous fluid. Participants in this observational study undergo pars plana vitrectomy (PPV) surgery as part of their usual care. During surgery, 100 to 250 microliters of vitreous fluid, which is typically discarded, are collected for NMR analysis. No additional interventions are performed as part of the study; it only involves collection of preoperative medical information and leftover vitreous fluid samples. Throughout the study, participants provide their medical history and preoperative examination information. Researchers analyze the collected vitreous fluid to measure relative concentrations of amino acids and macromolecules like glucose and lipids. The study monitors these metabolomic profiles intraoperatively to explore differences between disease groups. This research may help reveal important metabolic changes in vitreoretinal diseases over the course of the study period ending in 2027.

Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.